Need help? Order a test

Developing and providing personalised cancer tests for doctors and patients

More about RGCC
Scroll down

Information for patients

We work with cancer patients to provide a range of personalised tests so you can choose the best treatment.

More patient information

Cancer tests

New methods and reliable tests to help deliver personalised treatment


RGCC CAMBISeq (cancer analysis, mutational burden and instability sequencing) provides next generation sequencing analysis on both DNA and RNA to help predict a patient’s response to immunotherapy and to detect variants.

View test

Array comparative genomic hybridisation (aCGH) RGCC

This test identifies chromosomal abnormalities – when either part of the genetic sequence in a chromosome is deleted or added to – that might lead to cancer. It uses a technique called array CGH to identify abnormalities in a genome more clearly than traditional microscopes can. These abnormalities could be linked with parts of regions […]

View test


This test focuses on the status of a patient’s immune system. The test uses specific cellular markers, and the production of proteins called cytokines, to detect the type or types of cells that are responsible for switching a patient’s immune system on and off. Immune-Frame uses two different assays: the ELISA assay is used to […]

View test

Metastat RGCC

This test provides information, based on the detection of circulating tumour cells, about whether and where the tumour is likely to spread. Studies show that the cancer cells that have the potential to spread from the primary tumour express specific genes and proteins, or markers. These markers vary according to the organ that the tumour […]

View test


This test relies on pharmacogenomics. This is the science of inherited variations in genes, how these inherited variations dictate a patient’s response to a drug, and the ways these variations can be used to predict whether a patient will have a good or bad response to a drug, or no response at all. ChemoSNiP tests […]

View test

Onconomics Extracts

This test provides information about the efficacy of natural biological substances or extracts on circulating tumour cells. Onconomics Extracts focuses on testing using three methods: testing for the direct effect of an anti-cancer treatment, stimulating the immune system and inhibiting proliferative signals in the cancer cells that stimulate them to grow.

View test

Onconomics Plus RGCC

This test provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. Onconomics Plus RGCC is based on three methods: testing for the direct effect […]

View test

Onconomics RGCC

This test provides information about the effect of specific anti-cancer drugs and targeted therapies on a single patient. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays.

View test

Oncotrail RGCC

This test provides information about the presence of circulating tumour cells, their concentration, and immunophenotype for specific types of malignancies. This test is a tailor-made test for certain cancers: such as breast cancer (for which we provide the Oncotrail RGCC for breast cancer) and prostate cancer (for which we provide Oncotrail RGCC for prostate cancer. […]

View test

Oncotrace RGCC

This test provides information about the presence of circulating tumour cells, and their concentration and immunophenotype, which may help identify their origin. It is used to provide guidance about a patient’s prognosis, and to help identify the primary tumour when this is unknown.

View test

Oncocount RGCC

This test detects the presence of circulating tumour cells, and measures their concentration in the blood. As these cells that could lead to the recurrence of a cancer, this test is useful to detect relapse early, and as a follow-up tool.

View test
See all RGCC tests

Use our ‘smart filter’ to identify which test is best for your patients

Find out more

News & events

Find out more about our latest research, trials and education days

Liquid Biopsy: From Bench to Bed

On September 19th, 2020, we welcomed clinicians from the wider area. Dr. Papasotiriou and the members of the Research and Development Department presented the workflow they follow, including Cells Isolation, Targets Identification and Validation, Small Molecular Weight molecules production, Monoclonal Antibodies production as well as Pharmaceutical formulation of all products. At the final part, clinicians […]

Read more

Nutrition as a ‘precision medicine’ in cancer treatment

We know that a healthy diet and good nutrition might contribute in reduction of risk of certain cancers. Diets that are high in plant foods – such as fruit, vegetables, wholegrains and beans – may protect against certain cancers. For example, diets with a high proportion of these fibre-rich foods can protect against bowel cancer. […]

Read more

Liquid biopsy blood tests could be used to diagnose brain tumours

Results of a promising trial in people with brain tumours suggests that a specific blood test could be used for more accurate diagnosis, without the need for invasive procedures. The blood test based on circulating-tumour DNA (ctDNA) has been found to accurately classify different types of brain tumours and could allow for better treatment planning […]

Read more

Simple blood tests can be used to look for resistance to chemotherapy

When it comes to treating cancer, there’s good news and bad news. Part of the good news is that there are many effective medicines, known as chemotherapies, that can treat cancer and improve survival. The not so good news is that some cancers that initially respond to chemotherapy can become resistant to treatment. This means […]

Read more

Circulating tumour cells may predict breast cancer outcomes

Breast cancer is the second most common cancer worldwide and there were over 2 million new cases in 2018, according to the World Cancer Research Fund. So there is great research interest in understanding more about what determines how likely people with breast cancer are to survive, and to respond to treatment. Researchers at Cleveland […]

Read more

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more